LLY

1,196.03

0.86% 10.16

시장 영업 전: 1199.68 3.65 +0.31%

일라이 릴리 (LLY)

개요 뉴스 가격 이력 옵션 체인 Financials LLY 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$1,185.87

열려 있는:

$1194.35

하루 거래량:

1.98M

Relative Volume:

0.63

시가총액:

$1.07T

수익:

$72.25B

순이익/손실:

$25.28B

주가수익비율:

43.05

EPS:

27.781

순현금흐름:

$10.37B

1주 성능:

+1.43%

1개월 성능:

+7.05%

6개월 성능:

+12.38%

1년 성능:

+48.50%

1일 변동 폭

$1,187.50

$1,206.94

1주일 범위

$1,139.00

$1,206.94

52주 변동 폭

$623.78

$1,249.45

일라이 릴리 Stock (LLY) Company Profile

명칭

Lilly Eli Co

부문

Healthcare (1071)

산업

Drug Manufacturers - General (20)

전화

(317) 276-2000

주소

LILLY CORPORATE CTR, INDIANAPOLIS, IN

직원

50,000

트위터

@LillyPad

다음 수익 날짜

2026-08-05

최신 SEC 제출 서류

LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
LLY Lilly Eli Co	1,196.03	1.07T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	263.40	634.77B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	259.36	458.24B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	131.07	323.72B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	155.01	294.63B	54.66B	13.58B	16.05B	7.0171

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-17	다운그레이드	HSBC Securities	Hold → Reduce
2026-02-25	개시	RBC Capital Mkts	Outperform
2026-02-20	개시	Barclays	Overweight
2026-01-07	재개	UBS	Buy
2025-12-16	업그레이드	Daiwa Securities	Neutral → Buy
2025-12-15	재확인	BofA Securities	Buy
2025-12-15	재확인	Goldman	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-11-10	업그레이드	Leerink Partners	Market Perform → Outperform
2025-10-20	재확인	BMO Capital Markets	Outperform
2025-10-14	업그레이드	Erste Group	Hold → Buy
2025-09-17	다운그레이드	Berenberg	Buy → Hold
2025-08-27	업그레이드	HSBC Securities	Reduce → Hold
2025-08-18	다운그레이드	Daiwa Securities	Outperform → Neutral
2025-08-07	다운그레이드	Leerink Partners	Outperform → Market Perform
2025-06-05	다운그레이드	Erste Group	Buy → Hold
2025-04-28	다운그레이드	HSBC Securities	Buy → Reduce
2025-04-22	개시	Cantor Fitzgerald	Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-10-17	개시	Bernstein	Outperform
2024-09-13	재개	Citigroup	Buy
2024-08-12	업그레이드	Deutsche Bank	Hold → Buy
2024-02-21	다운그레이드	DZ Bank	Buy → Hold
2024-02-16	재확인	Morgan Stanley	Overweight
2023-12-21	다운그레이드	Daiwa Securities	Buy → Outperform
2023-11-09	개시	Deutsche Bank	Hold
2023-10-20	재개	UBS	Buy
2023-08-09	업그레이드	Jefferies	Hold → Buy
2023-07-26	재확인	Citigroup	Buy
2023-07-14	개시	HSBC Securities	Buy
2023-05-24	재확인	BofA Securities	Buy
2023-05-24	재확인	UBS	Buy
2023-03-13	업그레이드	Wells Fargo	Equal Weight → Overweight
2023-03-06	개시	Jefferies	Hold
2023-02-15	다운그레이드	Societe Generale	Hold → Sell
2022-11-18	개시	Credit Suisse	Outperform
2022-09-22	업그레이드	UBS	Neutral → Buy
2022-05-23	개시	SVB Leerink	Outperform
2022-04-06	재개	Morgan Stanley	Overweight
2022-03-10	개시	Daiwa Securities	Outperform
2022-01-21	업그레이드	DZ Bank	Hold → Buy
2022-01-03	재확인	Bernstein	Mkt Perform
2021-12-17	개시	Goldman	Neutral
2021-12-16	재확인	BMO Capital Markets	Outperform
2021-12-16	재확인	BofA Securities	Buy
2021-12-09	재개	Wells Fargo	Equal Weight
2021-11-19	개시	BMO Capital Markets	Outperform
2021-10-11	업그레이드	Berenberg	Hold → Buy
2021-09-29	업그레이드	Citigroup	Neutral → Buy
2021-08-05	업그레이드	DZ Bank	Hold → Buy
2021-07-27	재개	Truist	Buy
2021-06-24	재확인	Cantor Fitzgerald	Overweight
2021-01-19	업그레이드	Mizuho	Neutral → Buy
2020-12-10	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-11-10	재개	Bernstein	Mkt Perform
2020-09-29	개시	Berenberg	Hold
2020-09-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-06-16	업그레이드	Guggenheim	Neutral → Buy
2020-04-21	다운그레이드	UBS	Buy → Neutral
2020-04-09	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-02-06	개시	Mizuho	Neutral
2019-12-18	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2019-10-17	재개	BofA/Merrill	Buy
2019-05-28	개시	Goldman	Buy
2019-04-24	업그레이드	Edward Jones	Hold → Buy
2019-04-11	다운그레이드	Guggenheim	Buy → Neutral
2019-03-12	개시	JP Morgan	Overweight
2019-01-23	개시	UBS	Buy
2018-11-26	다운그레이드	Citigroup	Buy → Neutral
2018-10-31	업그레이드	Credit Suisse	Underperform → Neutral
2018-10-09	개시	Guggenheim	Buy
2018-10-01	재확인	SunTrust	Buy
2018-09-26	재개	JP Morgan	Overweight

모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

04:56 AM

Eli Lilly (NYSE:LLY) climbs into the spotlight as weight-loss drug demand runs hot - Kalkine Media

04:56 AM

01:05 AM

Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide - NewsNation

01:05 AM

Jul 26, 2026

Caxton Associates LLP Has $1.40 Million Stock Position in Eli Lilly and Company $LLY - InsuranceNewsNet

Jul 26, 2026

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? - The Motley Fool

Jul 26, 2026

Jul 25, 2026

Eli Lilly (NYSE:LLY): High-Growth Stock with Strong Technical and Fundamental Momentum - ChartMill

Jul 25, 2026

Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts - Yahoo Finance

Jul 25, 2026

Jul 24, 2026

Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO - Bloomberg.com

Jul 24, 2026

Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads - Law360

Jul 24, 2026

Novo Nordisk Sues Eli Lilly Over Misleading Ads - Intellectia AI

Jul 24, 2026

Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising - Yahoo Finance

Jul 24, 2026

Novo Nordisk seeks preliminary injunction days after suing Eli Lilly - MobiHealthNews

Jul 24, 2026

Novo Nordisk Seeks Pause on Eli Lilly’s Weight Loss Drug Ads - Bloomberg Law News

Jul 24, 2026

Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal - Endpoints News

Jul 24, 2026

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads - PharmaLive

Jul 24, 2026

Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads - Yahoo Finance

Jul 24, 2026

Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race - Stocktwits

Jul 24, 2026

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads - Yahoo Finance

Jul 24, 2026

The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements - medwatch.com

Jul 24, 2026

This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly - Forbes

Jul 24, 2026

Novo Nordisk seeks court order to halt Eli Lilly drug ads - Investing.com Nigeria

Jul 24, 2026

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads - Yahoo Finance UK

Jul 24, 2026

Novo Nordisk’s fight against Eli Lilly has gone legal: A top lawyer evaluates the case - Business Post

Jul 23, 2026

Eli Lilly and Company Price Today | XLLY Live Price, Chart & Market Cap - OKX

Jul 23, 2026

Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec - Pharmaceutical Executive

Jul 23, 2026

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising Claims - Law Commentary

Jul 23, 2026

Lilly's Next-Generation Obesity Shot Clears Another Hurdle - Yahoo Finance UK

Jul 23, 2026

Eli Lilly (NYSE:LLY) Shapes the Healthcare Earnings Narrative - Kalkine Media

Jul 23, 2026

Lilly Targets Early 2027 Filing for Next Obesity Drug - Yahoo Finance

Jul 23, 2026

Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing - Yahoo Finance

Jul 23, 2026

Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive

Jul 23, 2026

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application - Reuters

Jul 23, 2026

Lilly to file for next-gen obesity drug approval in early 2027 - Yahoo Finance

Jul 23, 2026

Eli Lilly (NYSE:LLY) Growth & Technical Setup Signal A Key Market Test - Kalkine Media

Jul 23, 2026

Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data - BioSpace

Jul 23, 2026

Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake - Stock Titan

Jul 23, 2026

How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - Yahoo Finance UK

Jul 23, 2026

Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average - Forbes

Jul 23, 2026

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors - simplywall.st

Jul 23, 2026

Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads - Stocktwits

Jul 23, 2026

Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle - Bloomberg.com

Jul 23, 2026

Eli Lilly (LLY) Advances Next-Gen Weight-Loss Therapy with Promi - GuruFocus

Jul 23, 2026

Eli Lilly presents positive safety data but postpones weight-loss candidate application - medwatch.com

Jul 23, 2026

Eli Lilly to File FDA Approval for Retatrutide in 2027 After Five Positive Phase 3 Trials - MLQ.ai

Jul 23, 2026

Eli Lilly and Co.'s next-generation obesity drug has had its market application delayed until 2027. - 富途牛牛

Jul 23, 2026

Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat - GuruFocus

Jul 23, 2026

Eli Lilly to seek obesity drug approval in Q1 2027 - Breakingthenews.net

Jul 23, 2026

Eli Lilly to seek approval for powerful new obe... - Pluang

Jul 23, 2026

Lilly’s retatrutide meets endpoints in two phase 3 obesity trials - Investing.com

Jul 23, 2026